Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 296,455,392
  • Shares Outstanding, K 1,767,140
  • Annual Sales, $ 54,318 M
  • Annual Income, $ 4,863 M
  • EBIT $ 13,822 M
  • EBITDA $ 22,520 M
  • 60-Month Beta 0.63
  • Price/Sales 5.42
  • Price/Cash Flow 10.53
  • Price/Book 48.49

Options Overview Details

View History
  • Implied Volatility 19.90% ( -0.56%)
  • Historical Volatility 45.61%
  • IV Percentile 46%
  • IV Rank 27.87%
  • IV High 30.36% on 10/29/24
  • IV Low 15.86% on 03/01/24
  • Put/Call Vol Ratio 1.53
  • Today's Volume 46,966
  • Volume Avg (30-Day) 35,054
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 417,756
  • Open Int (30-Day) 370,576

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 2.99
  • Number of Estimates 10
  • High Estimate 3.10
  • Low Estimate 2.96
  • Prior Year 2.79
  • Growth Rate Est. (year over year) +7.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
163.81 +4.83%
on 11/19/24
207.32 -17.17%
on 10/31/24
-14.81 (-7.94%)
since 10/21/24
3-Month
163.81 +4.83%
on 11/19/24
207.32 -17.17%
on 10/31/24
-24.80 (-12.62%)
since 08/21/24
52-Week
137.65 +24.76%
on 11/29/23
207.32 -17.17%
on 10/31/24
+33.00 (+23.79%)
since 11/21/23

Most Recent Stories

More News
Where Will AbbVie Be in 5 Years?

Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine, and AbbVie (NYSE: ABBV) is no exception. Nonetheless, the next five years...

ABBV : 171.73 (+2.37%)
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip

Last year, pharmaceutical giant AbbVie (NYSE: ABBV) lost patent exclusivity for its biggest cash cow, immunology medicine Humira. The drugmaker has rebounded quite nicely since. AbbVie returned to top-line...

ABBV : 171.73 (+2.37%)
3 Oversold Dividend Aristocrats Ready To Explode in 2025

These three companies all have one thing in common: they are all on sale.

KO : 63.76 (+1.22%)
JNJ : 155.50 (+1.56%)
ABBV : 171.73 (+2.37%)
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY announcing their results. AbbVie’s ABBV schizophrenia candidate, added from a recent...

BAYRY : 5.0900 (-0.97%)
AZN : 64.26 (+1.68%)
JNJ : 155.50 (+1.56%)
MRK : 99.86 (+2.48%)
ABBV : 171.73 (+2.37%)
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine, its once-daily...

NVO : 102.63 (-2.51%)
GMAB : 20.47 (+0.10%)
LLY : 749.92 (-0.46%)
ABBV : 171.73 (+2.37%)
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock

The drugmaker has convincingly laid to rest the biggest threat to its top line.

ABBV : 171.73 (+2.37%)
2 Dividend Stocks to Buy Hand Over Fist in November

These companies have solid businesses and excellent dividend growth track records.

ABBV : 171.73 (+2.37%)
AMGN : 289.90 (+0.71%)
What's Behind the Insider Buying on This High-Yield Stock?

As the biopharma industry booms with breakthrough treatments and growing demand, this high-yield healthcare stock just received a strong vote of confidence from insider buying.

ABBV : 171.73 (+2.37%)
BMY : 58.23 (+0.60%)
Stock market today: Wall Street rolls higher as bitcoin bursts above $87,000

Most U.S. stocks rose on Wall Street, but drops for Nvidia and some other heavyweight Big Tech companies kept indexes in check

HUM : 295.71 (+0.59%)
NVDA : 146.67 (+0.53%)
$SPX : 5,948.71 (+0.53%)
CI : 330.07 (+2.07%)
JPM : 244.76 (+1.65%)
$DOWI : 43,870.35 (+1.06%)
ABBV : 171.73 (+2.37%)
$IUXX : 20,740.78 (+0.36%)
Stocks Settle Mostly Higher on President-Elect Trump’s Pro-Growth Promises

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.05%. Stocks on Monday...

MSTR : 397.28 (-16.16%)
AVGO : 163.94 (+0.42%)
SPNS : 27.55 (+1.59%)
ADI : 213.96 (+1.40%)
$IUXX : 20,740.78 (+0.36%)
COIN : 295.23 (-7.74%)
ZNZ24 : 109-205 (+0.13%)
MNDY : 276.26 (+6.19%)
TSLA : 339.64 (-0.70%)
GFS : 42.00 (+0.82%)
LRCX : 73.13 (+4.40%)
$DOWI : 43,870.35 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 179.35
2nd Resistance Point 175.90
1st Resistance Point 173.82
Last Price 171.73
1st Support Level 168.28
2nd Support Level 164.83
3rd Support Level 162.75

See More

52-Week High 207.32
Fibonacci 61.8% 180.71
Fibonacci 50% 172.49
Last Price 171.73
Fibonacci 38.2% 164.26
52-Week Low 137.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar